BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37258039)

  • 1. Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors.
    Stadler JC; Keller L; Mess C; Bauer AT; Koett J; Geidel G; Heidrich I; Vidal-Y-Sy S; Andreas A; Stramaglia C; Sementsov M; Haberstroh W; Deitert B; Hoehne IL; Reschke R; Haalck T; Pantel K; Gebhardt C; Schneider SW
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased von Willebrand factor ristocetin cofactor activity and increased ADAMTS13 antigen increase postoperative drainage after coronary artery bypass grafting.
    Mazur P; Plicner D; Zdziarska J; Sadowski J; Undas A
    Eur J Cardiothorac Surg; 2014 Feb; 45(2):e26-32. PubMed ID: 24351199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases.
    Cibor D; Owczarek D; Butenas S; Salapa K; Mach T; Undas A
    World J Gastroenterol; 2017 Jul; 23(26):4796-4805. PubMed ID: 28765701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet Count, ADAMTS13 Activity, von Willebrand Factor Level and Survival in Patients with Colorectal Cancer: 5-Year Follow-up Study.
    Garam N; Maláti É; Sinkovits G; Gombos T; Szederjesi A; Barabás L; Gráf L; Kocsis J; Prohászka Z
    Thromb Haemost; 2018 Jan; 118(1):123-131. PubMed ID: 29304532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma.
    Takaya H; Namisaki T; Shimozato N; Kaji K; Kitade M; Moriya K; Sato S; Kawaratani H; Akahane T; Matsumoto M; Yoshiji H
    World J Gastrointest Oncol; 2019 May; 11(5):424-435. PubMed ID: 31139312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
    Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-lasting prothrombotic state implied by changes of plasma von Willebrand factor parameters after radical prostatectomy for prostate malignancy.
    Harsfalvi J; Molnar Z; Csanyi MC; Domjan I; Flasko T; Kaposi A; Benyo M
    Urol Oncol; 2020 Apr; 38(4):191-197. PubMed ID: 31711834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the Diagnostic Value of Plasma Levels, Activities, and Their Ratios of von Willebrand Factor and ADAMTS13 in Patients with Cerebral Infarction.
    Qu L; Jiang M; Qiu W; Lu S; Zhao Y; Xia L; Ruan C; Zhao Y
    Clin Appl Thromb Hemost; 2016 Apr; 22(3):252-9. PubMed ID: 25916953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity: Usefulness as a Prognostic Biomarker in Acute-on-Chronic Liver Failure.
    Takaya H; Namisaki T; Enomoto M; Kubo T; Tsuji Y; Fujinaga Y; Nishimura N; Kaji K; Kawaratani H; Moriya K; Akahane T; Matsumoto M; Yoshiji H
    Biology (Basel); 2023 Jan; 12(2):. PubMed ID: 36829443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma.
    Guida M; Bartolomeo N; Quaresmini D; Quaglino P; Madonna G; Pigozzo J; Di Giacomo AM; Minisini AM; Tucci M; Spagnolo F; Occelli M; Ridolfi L; Queirolo P; De Risi I; Valente M; Sciacovelli AM; Chiarion Sileni V; Ascierto PA; Stigliano L; Strippoli S
    J Transl Med; 2022 Apr; 20(1):159. PubMed ID: 35382857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Von Willebrand Factor, ADAMTS13, and the Risk of Mortality: The Rotterdam Study.
    Sonneveld MA; Franco OH; Ikram MA; Hofman A; Kavousi M; de Maat MP; Leebeek FW
    Arterioscler Thromb Vasc Biol; 2016 Dec; 36(12):2446-2451. PubMed ID: 27737864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. von Willebrand Factor Antigen, von Willebrand Factor Propeptide, and ADAMTS13 in Carotid Stenosis and Their Relationship with Cerebral Microemboli.
    Murphy SJX; Lim ST; Hickey F; Kinsella JA; Smith DR; Tierney S; Egan B; Feeley TM; Murphy SM; Collins DR; Coughlan T; O'Neill D; Harbison JA; Madhavan P; O'Neill SM; Colgan MP; O'Donnell JS; O'Sullivan JM; Hamilton G; McCabe DJH
    Thromb Haemost; 2021 Jan; 121(1):86-97. PubMed ID: 32932544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered von Willebrand Factor and ADAMTS13 Levels in Children With Cirrhosis and Extrahepatic Portal Hypertension.
    Islek A; Ilhan D; Ozturk N; Guven B; Sag E
    J Pediatr Hematol Oncol; 2021 Oct; 43(7):e951-e956. PubMed ID: 33369998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: Evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy.
    Henry BM; Benoit SW; de Oliveira MHS; Lippi G; Favaloro EJ; Benoit JL
    Int J Lab Hematol; 2021 Jul; 43 Suppl 1(Suppl 1):129-136. PubMed ID: 33270980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of von Willebrand factor and ADAMTS13 in patients with COVID-19: A systematic review and meta-analysis.
    Xu X; Feng Y; Jia Y; Zhang X; Li L; Bai X; Jiao L
    Thromb Res; 2022 Oct; 218():83-98. PubMed ID: 36027630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
    Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
    Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality.
    Sinkovits G; Réti M; Müller V; Iványi Z; Gál J; Gopcsa L; Reményi P; Szathmáry B; Lakatos B; Szlávik J; Bobek I; Prohászka ZZ; Förhécz Z; Mező B; Csuka D; Hurler L; Kajdácsi E; Cervenak L; Kiszel P; Masszi T; Vályi-Nagy I; Prohászka Z
    Thromb Haemost; 2022 Feb; 122(2):240-256. PubMed ID: 35062036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between ADAMTS13 activity, von Willebrand factor antigen levels and platelet function in the early and late phases after TIA or ischaemic stroke.
    McCabe DJ; Murphy SJ; Starke R; Harrison P; Brown MM; Sidhu PS; Mackie IJ; Scully M; Machin SJ
    J Neurol Sci; 2015 Jan; 348(1-2):35-40. PubMed ID: 25498844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
    Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of blood cell count-derived ratios in BRAF-mutated metastatic melanoma.
    Kopecky J; Kubecek O; Priester P; Vosmikova H; Cermakova E; Kyllarova A
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Dec; 166(4):393-404. PubMed ID: 34446937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.